Covered recipient · General Payments record
PHAEDRA LIPSEY
Eye and Vision Services Providers Optometrist
General Payments · PY2023–2024
$1,183.32
- Reported across 29 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $587.80 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Alcon Laboratories Inc | $164.37 | 3 |
| Dompe US, Inc. | $120.83 | 1 |
| BIOTISSUE HOLDINGS INC. | $98.72 | 1 |
| ABBVIE INC. | $62.42 | 3 |
| Genentech USA, Inc. | $44.84 | 2 |
| Bausch & Lomb Americas Inc. | $42.26 | 2 |
| Alimera Sciences, Inc. | $21.49 | 1 |
| Oyster Point Pharma, Inc. | $17.15 | 1 |
| Tarsus Pharmaceuticals, Inc. | $15.72 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $20.84 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104888339 | CMS |
| ABBVIE INC. | $20.83 | 06/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104888341 | CMS |
| ABBVIE INC. | $20.75 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104888343 | CMS |
| Alcon Vision LLC | $15.57 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110719670 | CMS |
| Alcon Vision LLC | $108.82 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110719674 | CMS |
| Alcon Vision LLC | $39.98 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110719672 | CMS |
| Alimera Sciences, Inc. | $21.49 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092839942 | CMS |
| Bausch & Lomb Americas Inc. | $22.41 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140427180 | CMS |
| Bausch & Lomb Americas Inc. | $19.85 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140427182 | CMS |
| BIOTISSUE HOLDINGS INC. | $98.72 | 04/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148778625 | CMS |
| Dompe US, Inc. | $120.83 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151413615 | CMS |
| Genentech USA, Inc. | $22.20 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133088618 | CMS |
| Genentech USA, Inc. | $22.64 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133088622 | CMS |
| Oyster Point Pharma, Inc. | $17.15 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147416160 | CMS |
| Tarsus Pharmaceuticals, Inc. | $15.72 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139112715 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.